Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The evolution of synthetic oral drug properties.

Literature DB >> 15686918

The evolution of synthetic oral drug properties.

Abstract

An analysis of the properties of 1791 synthetic, oral drugs approved and/or marketed since 1937 demonstrates that the median molecular weight of oral drugs has increased substantially over the past 60 years. Fewer than 5% of approved/marketed oral drugs have more than 4-H bond donors and just 2% have MW>500 and >3 H-bond donors.

Mesh：

Substances：

Year: 2005 PMID： 15686918 DOI： 10.1016/j.bmcl.2004.12.024

Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823

Keyword Cloud
Cited

23 in total

1. Associating Drugs, Targets and Clinical Outcomes into an Integrated Network Affords a New Platform for Computer-Aided Drug Repurposing.

Authors: Tudor I Oprea; Sonny Kim Nielsen; Oleg Ursu; Jeremy J Yang; Olivier Taboureau; Stephen L Mathias; Lrene Kouskoumvekaki; Larry A Sklar; Cristian G Bologa
Journal: Mol Inform Date: 2011-03-14 Impact factor: 3.353

Review 2. The influence of the 'organizational factor' on compound quality in drug discovery.

Authors: Paul D Leeson; Stephen A St-Gallay
Journal: Nat Rev Drug Discov Date: 2011-09-30 Impact factor: 84.694

3. Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes.

Authors: Travis T Wager; Ramalakshmi Y Chandrasekaran; Xinjun Hou; Matthew D Troutman; Patrick R Verhoest; Anabella Villalobos; Yvonne Will
Journal: ACS Chem Neurosci Date: 2010-03-25 Impact factor: 4.418

The evolution of synthetic oral drug properties.

1. Associating Drugs, Targets and Clinical Outcomes into an Integrated Network Affords a New Platform for Computer-Aided Drug Repurposing.

Review 2. The influence of the 'organizational factor' on compound quality in drug discovery.

3. Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes.

4. Quantifying the chemical beauty of drugs.

5. Characterization of biaryl torsional energetics and its treatment in OPLS all-atom force fields.

Review 6. The role of ligand efficiency metrics in drug discovery.

7. Data Sets Representative of the Structures and Experimental Properties of FDA-Approved Drugs.

Review 8. Hydrophobicity--shake flasks, protein folding and drug discovery.

9. Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening.

10. Let's not forget tautomers.